Combination of TATE and PD-1 Inhibitor in Liver Cancer

Combination of TATE and PD-1 Inhibitor in Liver Cancer
Experimental: Advanced Hepatocellular carcinoma

PD-1 inhibitor (Nivolumab 360 mg Q3W IV ) starts at day 1, and continues until progression.

TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization.

Drug: Nivolumab Injectable Product

a PD-1 immune check inhibitor

Other Name: OPDIVO

Combination Product: Trans-arterial tirapazamine embolization

Embolization with Lipiodol and Gelfoam

Source: View full study details on

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 22, 2023Comments | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine